Telli M, Litton J, Beck J, Jones J, Andersen J, Mina L
Breast Cancer. 2024; 31(5):886-897.
PMID: 38869771
PMC: 11341741.
DOI: 10.1007/s12282-024-01603-4.
Hecht F, Zocchi M, Alimohammadi F, Harris I
Mol Cell. 2023; 84(1):23-33.
PMID: 38029751
PMC: 10843710.
DOI: 10.1016/j.molcel.2023.11.001.
Del Giglio A, Alves B, Murad A, Fonseca F
J Med Case Rep. 2023; 17(1):407.
PMID: 37743480
PMC: 10519093.
DOI: 10.1186/s13256-023-04139-x.
Brown T, Yablonovitch A, Till J, Yen J, Kiedrowski L, Hood R
Clin Cancer Res. 2023; 29(24):5207-5216.
PMID: 37486343
PMC: 10806928.
DOI: 10.1158/1078-0432.CCR-23-1467.
Wei C, Shehayeb S, Lugo Santiago N, Kruper L, Han E, Wang E
PLoS One. 2023; 18(6):e0286998.
PMID: 37310942
PMC: 10263324.
DOI: 10.1371/journal.pone.0286998.
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
Bhin J, Paes Dias M, Gogola E, Rolfs F, Piersma S, de Bruijn R
Cell Rep. 2023; 42(5):112538.
PMID: 37209095
PMC: 10242444.
DOI: 10.1016/j.celrep.2023.112538.
Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge.
Keane F, Bajwa R, Selenica P, Park W, Roehrl M, Reis-Filho J
NPJ Precis Oncol. 2023; 7(1):40.
PMID: 37087482
PMC: 10122663.
DOI: 10.1038/s41698-023-00376-x.
Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
Darabi S, Braxton D, Xiu J, Carneiro B, Swensen J, Antonarakis E
Medicina (Kaunas). 2022; 58(12).
PMID: 36557020
PMC: 9785940.
DOI: 10.3390/medicina58121818.
Influence of germline genotype on the survival of patients with triple-negative breast cancer.
Villarreal-Garza C, Ferrigno A, Aranda-Gutierrez A, Frankel P, Ruel N, Fonseca A
Cancer Res Commun. 2022; 1(3):140-147.
PMID: 35875314
PMC: 9307147.
DOI: 10.1158/2767-9764.crc-21-0099.
PARP Inhibitors: A New Horizon for Patients with Prostate Cancer.
Congregado B, Rivero I, Osman I, Saez C, Medina Lopez R
Biomedicines. 2022; 10(6).
PMID: 35740437
PMC: 9220343.
DOI: 10.3390/biomedicines10061416.
Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing.
Jalloul N, Gomy I, Stokes S, Gusev A, Johnson B, Lindeman N
JCO Precis Oncol. 2021; 5.
PMID: 34820595
PMC: 8608266.
DOI: 10.1200/PO.21.00279.
Multimodality therapy in metastatic pancreas cancer with a mutation and durable long-term outcome: biology, intervention, or both?.
Sutton T, Grossberg A, Ey F, OReilly E, Sheppard B
Cancer Biol Ther. 2021; 22(10-12):532-536.
PMID: 34696697
PMC: 8726708.
DOI: 10.1080/15384047.2021.1991739.
Relevance of Platinum-free Interval and Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for g Advanced Breast Cancer (BROCADE3 Crossover).
Puhalla S, Dieras V, Arun B, Kaufman B, Wildiers H, Han H
Clin Cancer Res. 2021; 27(18):4983-4993.
PMID: 34131001
PMC: 9401555.
DOI: 10.1158/1078-0432.CCR-21-0748.
Clinical Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.
Pettitt S, Frankum J, Punta M, Lise S, Alexander J, Chen Y
Cancer Discov. 2020; 10(10):1475-1488.
PMID: 32699032
PMC: 7611203.
DOI: 10.1158/2159-8290.CD-19-1485.
Opportunities for improving cancer treatment using systems biology.
Griffiths J, Cohen A, Jones V, Salgia R, Chang J, Bild A
Curr Opin Syst Biol. 2020; 17:41-50.
PMID: 32518857
PMC: 7282416.
DOI: 10.1016/j.coisb.2019.10.018.
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review.
Pellegrino B, Musolino A, Llop-Guevara A, Serra V, Silva P, Hlavata Z
Transl Oncol. 2020; 13(2):410-422.
PMID: 31901781
PMC: 6948367.
DOI: 10.1016/j.tranon.2019.10.010.
Therapeutic targeting of and mutant breast cancer through mutant p53 reactivation.
Na B, Yu X, Withers T, Gilleran J, Yao M, Foo T
NPJ Breast Cancer. 2019; 5:14.
PMID: 30993195
PMC: 6465291.
DOI: 10.1038/s41523-019-0110-1.
